Figure S1



Figure S1: ApoB and Factor VII are effectively silenced in mouse liver. **a,b,** Mouse liver *Apob* (**a**) and *Factor VII* (**b**) mRNA levels normalized to *Cyclophilin* mRNA measured 2 days (2d) and 30 days (30d) after i.v. injections of phosphate buffered saline (PBS) or two different doses (5 mg kg^{-1} and 2 mg kg^{-1}) of formulated siRNA targeting *Apob* (si-ApoB), *Factor VII* (si-FVII) or *Luciferase* (si-Luc) (n=3 per group). Data are shown as mean±s.d.; asterisks denote statistical significance with p<0.01.

Figure S2



Figure S2: Liver mRNA levels of miR-122 targets are increased by antagomir treatment. Mouse liver *Aldo A, Hfe2, Tmed3, Lass6, lc35a4, Tmem50b* and *Gpx7* mRNA levels normalized to *Gapdh* mRNA measured 24 hr after three i.v. injections of 80 mg kg^{-1} cholesterol-conjugated RNA directed against miR-122 (antagomir-122), 80 mg kg^{-1} mismatch control (antagomir-122mm) or phosphate buffered saline (PBS) (n=6 per group). Data are shown as mean±s.d.

Figure S3



Figure S3: Liver protein levels of miR-122 targets are unaffected by siRNA treatment. Mouse liver protein levels of miR-122 targets AldoA and Iqgap1 were measured by Western analysis in liver lysates from siRNA- and PBS-treated animals. Tubulin levels are were measured to ensure equivalent protein loading.

Figure S4



Figure S4: Long-term silencing of SCAP in hamster liver by repeat administration of siRNA. a, Hamster liver *SCAP* mRNA levels normalized to *β-actin* mRNA measured seven days after three weekly i.v. injections of PBS, or 2.5 mg kg^{-1} formulated siRNA targeting SCAP (si-SCAP) or a mismatch control siRNA (si-SCAPmm). Data are shown as mean±s.d.; asterisk denotes statistical significance with p<0.01. **b,** Pooled hamster liver SCAP protein levels analyzed by immunoblot at the same time point as in **a**. Levels of Receptor Associated Protein (RAP) were detected to control for protein loading.

Table S1: Relative quantitation of mouse liver miRNA levels by nuclease protection assay. Mean values (±s.d.) for each treatment group are shown.

		PBS	ApoB 5mg/kg	ApoB 2mg/kg	FVII 5mg/kg	FVII 2mg/kg	Luc 5mg/kg
miR122	d2	1.0±0.15	1.0±0.13	1.0±0.06	1.0±0.05	1.1±0.02	1.0±0.01
	d30	1.0±0.08	1.0±0.06	1.1±0.11	1.0±0.03	1.0±0.05	1.1±0.09
miR16	d2	1.0±0.03	1.0±0.04	1.1±0.04	1.0±0.07	1.0±0.03	0.9±0.01
	d30	1.0±0.01	1.0±0.03	0.9±0.05	1.0±0.04	1.0±0.03	1.0±0.05
Let7a	d2	1.0±0.03	0.8±0.02	0.8±0.07	0.8±0.02	0.8±0.01	0.8±0.04
	d30	1.0±0.04	1.0±0.05	1.0±0.03	0.9±0.08	0.9±0.06	1.0±0.02